The Europe Gastrointestinal Therapeutics Market should witness market growth of 3.2% CAGR during the forecast period (2022-2028).
Most gastrointestinal drugs are designed to act locally, reducing systemic absorption as much as possible. When a prescription is absorbed systemically at low levels, informative pharmacokinetic and pharmacodynamic (PK/PD) drug profiles are difficult to obtain and usually require simulation and modeling. High-quality PK analysis is critical for making substantive arguments regarding the exposure-response relationship.
The gastrointestinal (GI) tract is a 25-foot-long pathway that extends from the anus to the mouth. Everything one eats passes through the esophagus and gets processed in the small intestine and the stomach to absorb nutrients. Finally, the waste is removed from the body through the colon and rectum. Sometimes a tumor can form in one of these organs due to the change in the DNA that causes abnormal cells to grow.
According to the UK National Screening Committee, stomach cancer tends to affect people aged 55 and above. It was seen as more common in men than in women. Presently bacterial infection causes around 40% of stomach cancers. It was found that people under 50 are developing stomach cancer due to various other factors, such as being obese. The burden of gastrointestinal and liver disease is heavy for patients. The NHS, and the economy, stated the gastrointestinal illness as the third most common cause of death, the leading cause of cancer death, and the most common reason of admission in hospitals.
The Germany market dominated the Europe Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2, 924.4 million by 2028. The UK market is anticipated to grow at a CAGR of 2.3% during (2022-2028). Additionally, The France market would exhibit a CAGR of 3.9% during (2022-2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Most gastrointestinal drugs are designed to act locally, reducing systemic absorption as much as possible. When a prescription is absorbed systemically at low levels, informative pharmacokinetic and pharmacodynamic (PK/PD) drug profiles are difficult to obtain and usually require simulation and modeling. High-quality PK analysis is critical for making substantive arguments regarding the exposure-response relationship.
The gastrointestinal (GI) tract is a 25-foot-long pathway that extends from the anus to the mouth. Everything one eats passes through the esophagus and gets processed in the small intestine and the stomach to absorb nutrients. Finally, the waste is removed from the body through the colon and rectum. Sometimes a tumor can form in one of these organs due to the change in the DNA that causes abnormal cells to grow.
According to the UK National Screening Committee, stomach cancer tends to affect people aged 55 and above. It was seen as more common in men than in women. Presently bacterial infection causes around 40% of stomach cancers. It was found that people under 50 are developing stomach cancer due to various other factors, such as being obese. The burden of gastrointestinal and liver disease is heavy for patients. The NHS, and the economy, stated the gastrointestinal illness as the third most common cause of death, the leading cause of cancer death, and the most common reason of admission in hospitals.
The Germany market dominated the Europe Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2, 924.4 million by 2028. The UK market is anticipated to grow at a CAGR of 2.3% during (2022-2028). Additionally, The France market would exhibit a CAGR of 3.9% during (2022-2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Scope of the Study
By Type
- Branded
- Generics
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Route of Administration
- Injectable
- Oral & Others
By Application
- Crohn's Disease
- Ulcerative Colitis
- GERD
- IBS
- Others
By Drug Class
- Biologics/Biosimilar
- Anti-Diarrheal
- Anti-Emetics
- Digestive Enzymes
- Aminosalicylates
- Proton Pump Inhibitors
- Laxatives & H2 Antagonists
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Gastrointestinal Therapeutics Market, by Type
1.4.2 Europe Gastrointestinal Therapeutics Market, by Distribution Channel
1.4.3 Europe Gastrointestinal Therapeutics Market, by Route of Administration
1.4.4 Europe Gastrointestinal Therapeutics Market, by Application
1.4.5 Europe Gastrointestinal Therapeutics Market, by Drug Class
1.4.6 Europe Gastrointestinal Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Gastrointestinal Therapeutics Market
Chapter 4. Europe Gastrointestinal Therapeutics Market by Type
4.1 Europe Branded Market by Country
4.2 Europe Generics Market by Country
Chapter 5. Europe Gastrointestinal Therapeutics Market by Distribution Channel
5.1 Europe Retail Pharmacies Market by Country
5.2 Europe Hospital Pharmacies Market by Country
5.3 Europe Online Pharmacies Market by Country
Chapter 6. Europe Gastrointestinal Therapeutics Market by Route of Administration
6.1 Europe Injectable Market by Country
6.2 Europe Oral & Others Market by Country
Chapter 7. Europe Gastrointestinal Therapeutics Market by Application
7.1 Europe Crohn's Disease Market by Country
7.2 Europe Ulcerative Colitis Market by Country
7.3 Europe GERD Market by Country
7.4 Europe IBS Market by Country
7.5 Europe Others Market by Country
Chapter 8. Europe Gastrointestinal Therapeutics Market by Drug Class
8.1 Europe Biologics/Biosimilar Market by Country
8.2 Europe Anti-Diarrheal Market by Country
8.3 Europe Anti-Emetics Market by Country
8.4 Europe Digestive Enzymes Market by Country
8.5 Europe Aminosalicylates Market by Country
8.6 Europe Proton Pump Inhibitors Market by Country
8.7 Europe Laxatives & H2 Antagonists Market by Country
8.8 Europe Others Market by Country
Chapter 9. Europe Gastrointestinal Therapeutics Market by Country
9.1 Germany Gastrointestinal Therapeutics Market
9.1.1 Germany Gastrointestinal Therapeutics Market by Type
9.1.2 Germany Gastrointestinal Therapeutics Market by Distribution Channel
9.1.3 Germany Gastrointestinal Therapeutics Market by Route of Administration
9.1.4 Germany Gastrointestinal Therapeutics Market by Application
9.1.5 Germany Gastrointestinal Therapeutics Market by Drug Class
9.2 UK Gastrointestinal Therapeutics Market
9.2.1 UK Gastrointestinal Therapeutics Market by Type
9.2.2 UK Gastrointestinal Therapeutics Market by Distribution Channel
9.2.3 UK Gastrointestinal Therapeutics Market by Route of Administration
9.2.4 UK Gastrointestinal Therapeutics Market by Application
9.2.5 UK Gastrointestinal Therapeutics Market by Drug Class
9.3 France Gastrointestinal Therapeutics Market
9.3.1 France Gastrointestinal Therapeutics Market by Type
9.3.2 France Gastrointestinal Therapeutics Market by Distribution Channel
9.3.3 France Gastrointestinal Therapeutics Market by Route of Administration
9.3.4 France Gastrointestinal Therapeutics Market by Application
9.3.5 France Gastrointestinal Therapeutics Market by Drug Class
9.4 Russia Gastrointestinal Therapeutics Market
9.4.1 Russia Gastrointestinal Therapeutics Market by Type
9.4.2 Russia Gastrointestinal Therapeutics Market by Distribution Channel
9.4.3 Russia Gastrointestinal Therapeutics Market by Route of Administration
9.4.4 Russia Gastrointestinal Therapeutics Market by Application
9.4.5 Russia Gastrointestinal Therapeutics Market by Drug Class
9.5 Spain Gastrointestinal Therapeutics Market
9.5.1 Spain Gastrointestinal Therapeutics Market by Type
9.5.2 Spain Gastrointestinal Therapeutics Market by Distribution Channel
9.5.3 Spain Gastrointestinal Therapeutics Market by Route of Administration
9.5.4 Spain Gastrointestinal Therapeutics Market by Application
9.5.5 Spain Gastrointestinal Therapeutics Market by Drug Class
9.6 Italy Gastrointestinal Therapeutics Market
9.6.1 Italy Gastrointestinal Therapeutics Market by Type
9.6.2 Italy Gastrointestinal Therapeutics Market by Distribution Channel
9.6.3 Italy Gastrointestinal Therapeutics Market by Route of Administration
9.6.4 Italy Gastrointestinal Therapeutics Market by Application
9.6.5 Italy Gastrointestinal Therapeutics Market by Drug Class
9.7 Rest of Europe Gastrointestinal Therapeutics Market
9.7.1 Rest of Europe Gastrointestinal Therapeutics Market by Type
9.7.2 Rest of Europe Gastrointestinal Therapeutics Market by Distribution Channel
9.7.3 Rest of Europe Gastrointestinal Therapeutics Market by Route of Administration
9.7.4 Rest of Europe Gastrointestinal Therapeutics Market by Application
9.7.5 Rest of Europe Gastrointestinal Therapeutics Market by Drug Class
Chapter 10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 SWOT Analysis
10.2 AbbVie, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Approvals and Trials:
10.3 Takeda Pharmaceutical Company Limited
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Partnerships, Collaborations, and Agreements:
10.3.5.2 Acquisition and Mergers:
10.4 Pfizer, Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Regional & Segmental Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.5 Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Product Launches and Product Expansions:
10.6 Johnson & Johnson (Janssen Global Services, LLC)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental &Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 AstraZeneca PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.8 Bayer AG
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental and Regional Analysis
10.8.4 Research & Development Expense
10.9 Sun Pharmaceutical Industries Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Research & Development Expenses
10.10. Cipla Limited
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expense
Companies Mentioned
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Methodology
LOADING...
